Opportunity Information: Apply for CDC RFA GH21 2169
The grant opportunity "Strengthening detection, prevention and response to infectious disease threats in Uzbekistan" (Funding Opportunity Number: CDC RFA GH21 2169) is a CDC-funded cooperative agreement under the U.S. Department of Health and Human Services, aimed at building Uzbekistan's public health laboratory and surveillance capacity. It is positioned as a continuation and expansion of work already underway at the Research Institute for Epidemiology, Microbiology and Infectious Diseases (RIEMID) under a prior CDC cooperative agreement focused on antimicrobial resistance (AMR). RIEMID is also formally recognized by the Government of Uzbekistan as a national center for genetic technologies under Presidential Decree PP-4790 (July 27, 2020), which sets the backdrop for CDC to deepen support around advanced laboratory genomics and national surveillance functions.
A central focus of the opportunity is the establishment of a Center for Genome Sequencing of Emerging and Re-Emerging Infectious Diseases at RIEMID. The intent is explicitly non-research and practical: CDC seeks to help RIEMID stand up and operationalize a sequencing program that can be used routinely for public health action. The activities described include training and mentorship for staff working at the new Center, procurement of specialized gene sequencing equipment, transfer and sharing of established pathogen sequencing methodologies, support for analyzing sequencing data, and building an understanding of why sharing genomic data with the global community matters. In other words, the award is designed to move beyond one-off sequencing and toward a sustainable, standardized capability where staff can generate, interpret, and communicate genomic results in ways that inform surveillance and response.
COVID-19 response capacity is a key driver of the sequencing component. By developing in-country genomic sequencing, Uzbekistan would be better equipped to detect, investigate, and report SARS-CoV-2 transmission patterns, including the ability to identify new strains and monitor mutations as they emerge. The opportunity emphasizes that sequencing data can clarify pathogen phylogeny, meaning it helps map how viruses and other pathogens evolve and spread over time. That kind of information can strengthen outbreak investigations, improve situational awareness for public health decision-making, and potentially contribute to vaccine-related efforts by improving understanding of circulating variants, especially if data are shared in ways that benefit both Uzbekistan and the broader international public health community.
Alongside genomics for emerging infections, the grant continues to prioritize antimicrobial resistance as a major infectious disease threat. CDC indicates it wants RIEMID to extend AMR surveillance to cover the entire country, not just selected sites or regions, suggesting a shift toward more comprehensive national coverage and more consistent reporting. The opportunity also calls for non-research activities that strengthen the rational use of antimicrobials, which typically refers to stewardship-oriented approaches that reduce unnecessary antibiotic use and help slow the development and spread of resistance. This part of the scope points to a broader strategy that connects laboratory surveillance (detecting resistance) with system-level interventions (reducing misuse and overuse).
The grant further highlights modernizing bacterial identification and AMR detection by introducing genetic surveillance and rapid identification systems such as MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight). MALDI-TOF is widely used to identify bacteria quickly and accurately in clinical and reference laboratories, which can improve turnaround time, support better patient management, and strengthen surveillance data quality. In addition, CDC underscores the importance of improving AMR data quality through implementation of a quality management system (QMS) in bacteriology laboratories. This implies work on standard operating procedures, quality control, staff competency, documentation practices, and consistency across laboratories, so that AMR data are reliable and comparable. Finally, the opportunity calls for consolidating AMR data within the RIEMID AMR reference center, indicating an intent to strengthen central coordination, data aggregation, and national-level analysis and reporting.
Administratively, this funding opportunity is listed as discretionary and uses a cooperative agreement mechanism, meaning CDC expects to have substantial involvement beyond simple grantmaking, typically through technical collaboration, guidance, and ongoing engagement. The activity category is health (CFDA number 93.318). The posting indicates an expected single award (ExpectedAwards: 1), suggesting the work is designed around a specific partner and national implementation pathway rather than a broad competitive pool. The opportunity was created May 11, 2021, with an original closing date of July 10, 2021, and applications were required to be submitted electronically by 11:59 p.m. Eastern Time on the due date. The listed award ceiling is shown as 0 in the source data, which often means the ceiling was not specified in that field rather than indicating no funding, and the eligibility category is presented as "Others" with additional eligibility clarification referenced in the full announcement.
Overall, the opportunity is aimed at building lasting national capacity in Uzbekistan by pairing infrastructure investments (sequencing and lab equipment) with workforce development (training and mentorship), standardized methods (shared protocols and analytics approaches), stronger quality systems (QMS in bacteriology labs), and improved national coordination (consolidated AMR data and expanded surveillance). The intended end state is a stronger, faster, and more reliable ability to detect infectious disease threats like COVID-19 variants and antimicrobial-resistant organisms, and to translate laboratory findings into public health action and reporting that aligns with global best practices.Apply for CDC RFA GH21 2169
- The Department of Health and Human Services, Centers for Disease Control - CGH in the health sector is offering a public funding opportunity titled "Strengthening detection, prevention and response to infectious disease threats in Uzbekistan" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.318.
- This funding opportunity was created on May 11, 2021.
- Applicants must submit their applications by Jul 10, 2021 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Strengthening detection, prevention and response to infectious disease threats in Uzbekistan (CDC RFA GH21-2169)
What is the name and identifier of this grant opportunity?
The opportunity is titled "Strengthening detection, prevention and response to infectious disease threats in Uzbekistan" and is listed under Funding Opportunity Number CDC RFA GH21 2169.
Who is funding and administering this opportunity?
This is a CDC-funded cooperative agreement under the U.S. Department of Health and Human Services (HHS).
What type of funding mechanism is used?
The mechanism is a cooperative agreement. That means CDC expects substantial involvement beyond issuing funds, typically including technical collaboration, guidance, and ongoing engagement during implementation.
Is this considered discretionary funding?
Yes. The listing describes the opportunity as discretionary.
What is the main goal of the award?
The overall goal is to strengthen Uzbekistan's public health laboratory and surveillance capacity so the country can better detect, prevent, and respond to infectious disease threats, including emerging infections and antimicrobial resistance (AMR).
Which institution in Uzbekistan is central to the planned work?
The work is positioned as a continuation and expansion of activities at the Research Institute for Epidemiology, Microbiology and Infectious Diseases (RIEMID).
How does this opportunity relate to earlier CDC work in Uzbekistan?
It is described as continuing and expanding work already underway at RIEMID under a prior CDC cooperative agreement focused on antimicrobial resistance (AMR).
What national policy context is mentioned for RIEMID?
RIEMID is formally recognized by the Government of Uzbekistan as a national center for genetic technologies under Presidential Decree PP-4790 (July 27, 2020). The opportunity references this as part of the backdrop for strengthening advanced laboratory genomics and national surveillance functions.
What major new capability is expected to be established at RIEMID?
A central focus is establishing a Center for Genome Sequencing of Emerging and Re-Emerging Infectious Diseases at RIEMID.
Is the sequencing component intended to be research-focused?
No. The intent is explicitly non-research and practical. The aim is to stand up and operationalize routine sequencing for public health action rather than one-off sequencing projects.
What kinds of activities are included to build sequencing capacity?
Activities described include training and mentorship for staff at the new Center, procurement of specialized gene sequencing equipment, transfer and sharing of established pathogen sequencing methodologies, support for analyzing sequencing data, and building understanding of why sharing genomic data with the global community matters.
What is meant by making sequencing "routine" for public health action?
The opportunity emphasizes building a sustainable, standardized capability where staff can generate, interpret, and communicate genomic results in ways that inform surveillance and response (not just produce sequences occasionally).
How is COVID-19 connected to the genomics work?
COVID-19 response capacity is described as a key driver. By developing in-country genomic sequencing, Uzbekistan would be better equipped to detect, investigate, and report SARS-CoV-2 transmission patterns, identify new strains, and monitor mutations as they emerge.
What does the opportunity say sequencing can contribute during outbreaks?
Sequencing data can clarify pathogen phylogeny (how pathogens evolve and spread over time). This can strengthen outbreak investigations, improve situational awareness for public health decision-making, and support reporting.
Does the opportunity mention sharing genomic data internationally?
Yes. It highlights building an understanding of why sharing genomic data with the global community matters, and notes that sharing can benefit both Uzbekistan and the broader international public health community.
Besides emerging infections, what other major threat area is prioritized?
Antimicrobial resistance (AMR) remains a major infectious disease threat and a continued priority within the scope of this opportunity.
What expansion is expected for AMR surveillance coverage?
CDC indicates it wants RIEMID to extend AMR surveillance to cover the entire country, suggesting a move toward comprehensive national coverage rather than surveillance limited to selected sites or regions.
Does the opportunity include activities related to antimicrobial stewardship?
Yes. It calls for non-research activities that strengthen the rational use of antimicrobials, which generally refers to stewardship-oriented approaches to reduce unnecessary antibiotic use and slow the development and spread of resistance.
What laboratory modernization approaches are specifically mentioned for bacterial identification and AMR detection?
The opportunity mentions introducing genetic surveillance and rapid identification systems such as MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight).
What is MALDI-TOF described as being used for?
MALDI-TOF is described as widely used to identify bacteria quickly and accurately in clinical and reference laboratories, improving turnaround time, supporting better patient management, and strengthening surveillance data quality.
How does the opportunity plan to improve AMR data quality?
It underscores implementing a quality management system (QMS) in bacteriology laboratories, implying work on standard operating procedures, quality control, staff competency, documentation practices, and consistency across laboratories so AMR data are reliable and comparable.
Where is AMR data expected to be coordinated or consolidated?
The opportunity calls for consolidating AMR data within the RIEMID AMR reference center to strengthen central coordination, data aggregation, and national-level analysis and reporting.
What is the activity category and CFDA number listed?
The activity category is health, and the CFDA number listed is 93.318.
How many awards were expected?
The posting indicates an expected single award (ExpectedAwards: 1).
What does an expected single award suggest about the design of the opportunity?
Based on the posting, it suggests the work is designed around a specific partner and a national implementation pathway rather than a broadly distributed competitive pool.
When was the opportunity created and when did it close?
The opportunity was created on May 11, 2021, and the original closing date was July 10, 2021.
How were applications required to be submitted and by what time?
Applications were required to be submitted electronically by 11:59 p.m. Eastern Time on the due date.
What is the listed award ceiling?
The listed award ceiling is shown as 0 in the source data. The description notes this often indicates the ceiling was not specified in that field rather than meaning no funding is available.
What is known about eligibility from the provided information?
The eligibility category is presented as "Others," with additional eligibility clarification referenced in the full announcement.
What are the major building blocks of the capacity-building approach described?
The opportunity emphasizes infrastructure investments (sequencing and lab equipment), workforce development (training and mentorship), standardized methods (shared protocols and analytics approaches), stronger quality systems (QMS in bacteriology labs), and improved national coordination (consolidated AMR data and expanded surveillance).
What is the intended end state of the award?
The intended end state is a stronger, faster, and more reliable ability to detect infectious disease threats (including COVID-19 variants and antimicrobial-resistant organisms) and to translate laboratory findings into public health action and reporting aligned with global best practices.
Browse more opportunities from the same category: Health
Next opportunity: Disrupting Operations of Illicit Supply Networks
Previous opportunity: Basic Education Quality Advancement Addendum
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH21 2169
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH21 2169) also looked into and applied for these:
| Funding Opportunity |
|---|
| Projects of National Significance: Empowering Youth with Intellectual and Developmental Disabilities to Manage Their Healthcare Transitions Apply for HHS 2021 ACL AOD DNCE 0100 Funding Number: HHS 2021 ACL AOD DNCE 0100 Agency: Department of Health and Human Services, Administration for Community Living Category: Health Funding Amount: $485,000 |
| Family-Centered Approaches to Improving Type 2 Diabetes Control and Prevention Apply for MP CPI 21 001 Funding Number: MP CPI 21 001 Agency: Department of Health and Human Services, Office of the Assistant Secretary for Health Category: Health Funding Amount: $500,000 |
| Community Led Monitoring Activity in the Kyrgyz Republic Apply for 72011521RFA00008 Funding Number: 72011521RFA00008 Agency: Agency for International Development, Kazakhstan USAID-Almaty Category: Health Funding Amount: $160,000 |
| National HIV Behavioral Surveillance (NHBS) Apply for CDC RFA PS22 2201 Funding Number: CDC RFA PS22 2201 Agency: Department of Health and Human Services, Centers for Disease Control - NCHHSTP Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 22 002 Funding Number: HRSA 22 002 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Area Health Education Centers (AHEC) - Simulation Education Training (SET) Competitive Supplement Apply for HRSA 21 103 Funding Number: HRSA 21 103 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Tribal Public Health Capacity-Building and Quality Improvement Umbrella Cooperative Agreement Apply for CDC RFA OT18 18030401SUPP21 Funding Number: CDC RFA OT18 18030401SUPP21 Agency: Department of Health and Human Services, Centers for Disease Control - OSTLTS Category: Health Funding Amount: Case Dependent |
| Shoulder to Shoulder: Accompanying Ministries of Health in Central America in Strengthening Local and Global Health Security Apply for CDC RFA GH21 2164 Funding Number: CDC RFA GH21 2164 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Optimizing Virtual Care (OVC) Apply for HRSA 22 097 Funding Number: HRSA 22 097 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $2,000,000 |
| Capacity Building and Strengthening of Hospital Infection Control to detect, prevent and respond to antimicrobial resistance in India Apply for CDC RFA GH21 2173 Funding Number: CDC RFA GH21 2173 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Discovery & Exploration of Emerging Pathogens – Viral Zoonoses (DEEP VZN) Apply for 7200AA21RFA00005 Funding Number: 7200AA21RFA00005 Agency: Agency for International Development Category: Health Funding Amount: $125,000,000 |
| American Rescue Plan Act - Pediatric Mental Health Care Access – New Area Expansion Apply for HRSA 21 122 Funding Number: HRSA 21 122 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $445,000 |
| Building the HIV Workforce and Strengthening Engagement in Communities of Color (B-SEC) Apply for HRSA 21 124 Funding Number: HRSA 21 124 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Community-Led Monitoring (CLM) of HIV Services in Sierra Leone Apply for HRSA 21 099 Funding Number: HRSA 21 099 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Healthy Start Initiative: Eliminating Disparities in Perinatal Health Supplement: Action Plans for Infant Health Equity Apply for HRSA 21 120 Funding Number: HRSA 21 120 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $80,000 |
| Local Community-Based Workforce to Increase COVID-19 Vaccine Access Apply for HRSA 21 140 Funding Number: HRSA 21 140 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 22 003 Funding Number: HRSA 22 003 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Service Area Competition Apply for HRSA 22 103 Funding Number: HRSA 22 103 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Delta Healthcare Services Grant Apply for RDBCP DHCS 2021 Funding Number: RDBCP DHCS 2021 Agency: Department of Agriculture, Business and Cooperative Programs Category: Health Funding Amount: $1,000,000 |
| Tunisian Health Center for University Research Excellence & Sustainability (CURES) Apply for SFOP0008125 Funding Number: SFOP0008125 Agency: Department of State, Assistance Coordination Category: Health Funding Amount: $5,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH21 2169", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.